Increased binding of the lectin peanut agglutinin is a common feature in epithelial malignancy and hyperplasia. This may have considerable functional importance in the intestine by allowing interaction between the epithelium and mitogenic lectins of dietary or microbial origin. Peanut agglutinin binds the disaccharide Thomsen-Friedenreich (TF, T or core 1) blood group antigen, Gal beta (1-3) GalNAc alpha-, but is not totally specific for this site. Consequently, there has been controversy about the presence of this structure in colon cancer; studies with anti-TF monoclonal antibodies have failed to detect it. We have examined the presence of TF antigen in colonic mucus glycoprotein (mucin) using endoalpha-N-acetylgalactosaminidase (O-Glycanase), which specifically catalyzes the hydrolysis of TF antigen from glycoconjugates. Samples of adenocarcinoma, inflammatory bowel disease (ulcerative colitis), and normal mucin were treated with O-glycanase, the liberated disaccharide was separated from the glycoprotein and analyzed using dual CarboPac PA-100 column high performance anion-exchange chromatography coupled with pulsed amperometric detection. O-Glycanase treatment released increased amounts of TF antigen from both colonic adenocarcinoma (8.0 +/-3.9 ng/micrograms protein, n = 11; P < 0.0001 ANOVA) and ulcerative colitis mucin (3.3 +/-0.3 ng/micrograms protein, n = 5; P = 0.04) compared with mucin samples from histologically normal mucosa distant from carcinoma (1.5 +/-1.1 ng/micrograms protein, n = 9). However, after mild acid treatment to remove […] 
Introduction
Increased binding of the lectin peanut agglutinin is a common feature in epithelial malignancy and hyperplasia. This may have considerable functional importance in the intestine by allowing interaction between the epithelium and mitogenic lectins of dietary or microbial origin. Peanut agglutinin binds the disaccharide Thomsen-Friedenreich (TF,T or core 1) blood group antigen, Gal,8(1-3)GalNAca-, but is not totally specific for this site. Consequently, there has been controversy about the presence of this structure in colon cancer; studies with anti-TF monoclonal antibodies have failed to detect it. We have examined the presence of TF antigen in colonic mucus glycoprotein (mucin) using endoa-N-acetylgalactosaminidase (O-Glycanase®), which specifically catalyzes the hydrolysis of TF antigen from glycoconjugates. Samples of adenocarcinoma, inflammatory bowel disease (ulcerative colitis), and normal mucin were treated with O-glycanase, the liberated disaccharide was separated from the glycoprotein and analyzed using dual CarboPac PA-100 column high performance anion-exchange chromatography coupled with pulsed amperometric detection. O-Glycanase treatment released increased amounts of TF antigen from both colonic adenocarcinoma (8.0±3.9 ng/,ug protein, n = 11; P < 0.0001 ANOVA) and ulcerative colitis mucin (3.3+0.3 ng/,ig protein, n = 5; P = 0.04) compared with mucin samples from histologically normal mucosa distant from carcinoma (1.5±1.1 ng/,g protein, n = 9). However, after mild acid treatment to remove sialic acids and fucose, releasable TF antigen was increased in all nine of these histologically normal mucin samples (5.5±2.6 ng/,ug protein, P < 0.0002). We conclude that TF antigen is an oncofetal antigen which is expressed in colon cancer, but is concealed by further glycosylation ( (1) (2) (3) , both within the cells and in secreted material (4, 5) , in adenomatous and metaplastic polyps (2, 3, 6) , and in the mucosa of patients with inflammatory bowel disease (7, 8) . PNA binding is not detectable in normal colonic mucosa (3, 6, 9) , unless sensitivity is increased by avidin-biotin amplification (2, 6) .
PNA has been shown previously to be mitogenic for normal human colonic epithelium ( 10) , colorectal cancer cell lines ( 10, 11) , and for colonic polyp and inflammatory bowel disease mucosa ( 12) . PNA binds to the disaccharide Thomsen-Friedenreich (TF) blood group antigen (Gal,61 -3GalNAca-) which is a core carbohydrate structure of O-linked oligosaccharides on glycoproteins ( 13) . It has been suggested that this disaccharide behaves as an oncofetal antigen in many epithelial tissues becoming expressed in hyperplasia and malignancy; for example, TF is expressed in neonatal colon and meconium (14, 15) but in normal adult epithelium it is thought to be masked by further glycosylation and/or sialylation (16, 17) . The hypothesis has been proposed (10) that increased expression of TF antigen by hyperplastic and malignant epithelia may be an important determinant of the altered proliferation, by allowing interaction with luminal Gal31 -3GalNAc-binding lectins of dietary and microbial origin.
However, there has been controversy about the presence of TF antigen in malignant tissues. PNA is not totally specific for TFa (Gal#3I -3GalNAca-, on glycoproteins), possessing a high degree of affinity for both TFf (GallI -3GalNAc/3-, on glycolipids) and some affinity for type 1 (Gal61 -3GlcNAc,61-3)n chains (18, 19) . This uncertainty has been increased by some studies which have failed to demonstrate TFa in colonic malignant tissue using carbohydrate-specific monoclonal antibodies (20, 21 ). In addition, a rigorous analysis of the oligosaccharides in normal adult colonic mucin failed to detect Gal,61 -3GalNAc as a core structure (22) . However, a study using D-galactose oxidase/Schiff's reagent (23) has suggested the presence of Gall6-3GalNAc in malignant tissues.
We have sought to clarify this confusion by specific quantification of TFa antigen released from histologically normal 1 . Abbreviations used in this paper: AFGP, Antarctic fish antifreeze glycopeptides; Gal, D-galactose; GaINAc, N-acetyl-D-galactosamine; ulcerative colitis and carcinomatous colonic mucin, using highpH anion-exchange chromatography (HPAEC) coupled with pulsed amperometric detection (PAD) after specific enzymatic release with endo-a-N-acetylgalactosaminidase (O-glycanase), which hydrolyzes glycosidic bonds formed by N-acetylgalactosamine and the hydroxyl group of either serine or threonine only when in the sequence Gal/3 -3GalNAc-a-O-Ser/Thr (24, 25 
Tissue specimens
Surgical resection specimens were obtained from 11 patients with malignant colorectal adenocarcinoma, from 9 of which adjacent histologically normal colonic tissue (at least 10 cm away from carcinoma) was available. Five active ulcerative colitis colectomy specimens were also obtained. Tissue was stored at -80°C before treatment.
Purification of colonic mucus glycoproteins (mucin)
Each surgical resection specimen was diced frozen and homogenized (100 mg tissue/ml) using a Polytron® (Kinematica GmbH, KriensLuzern, Switzerland), in phosphate-buffered saline (PBS), pH 7.4, containing a cocktail of protease inhibitors (2 MM aprotinin, 10 ,M leupeptin, 5 mM benzamidine hydrochloride, and 0.01% wt/vol thimerosal). Each homogenate was ultrasonicated and centrifuged using conditions described previously (26) , and supernatants were desalted on PD110-Sephadex GM25 (5 x 1.5 cm) columns (Pharmacia AB, Uppsala, Sweden). Contaminating proteoglycans were removed by successive incubation with collagenase (1 mg/ml in PBS, pH 7.4), hyaluronidase (1 mg/ ml in 20 mM phosphate buffer, pH 5.8), and protease-free chondroitin ABC lyase (0.02 U/ml in 0.01 M Tris-HCl, pH 8.0), each for 6 h, at 370C.
Mucin was purified from homogenates by Sepharose CL-2B minicolumns (5 X 1.5 cm) eluted with PBS, pH 7.4, after which the void volume was subjected to high performance gel filtration using Superose 6 as described previously (26) . Purified mucin was identified by ELISA using the CAM 17.1 anti-mucin monoclonal antibody (see reference 26) and assayed for protein using a bicinchoninic acid assay (kit BCA-1; Sigma Chemical Co.), expressed relative to a standard of bovine serum albumin (BSA).
Hydrolysis of Gal/1-3GalNAc using 0-glycanase O-Glycanase was supplied in 10 mM citrate/phosphate buffer, pH 6, containing 25% vol/vol glycerol. The glycerol interfered with HPAEC analysis and was removed by two passages through Bio-Gel P30 polyacrylamide gel columns (Bio-spin®; Bio-Rad Laboratories, Hercules, CA).
Lyophilized samples of purified colonic mucin (100 Mg protein)
were incubated with 0.6 mU deglycerolated O-glycanase in 100 pl 100 mM citrate/phosphate buffer, pH 6, containing 100 pig/ml BSA and 0.02% wt/vol sodium azide, for 18 h at 370C. Enzymatic release was confirmed using the antifreeze glycopeptides AFGP-I and AFGP-XV (0-100 [lg) and asialofetuin (0-200 pg) as control TF-expressing substrates (27, 28) . Appropriate control samples, incubated in the absence of O-glycanase and incubated with O-glycanase after pretreatment with bovine testis /3-galactosidase, were studied. O-Glycanase-liberated disaccharide was separated from intact glycoprotein and enzyme by sequential chromatography on Dowex 5OX-12 H+ form resin (3 x 0.5 cm), eluted with three column volumes of HPLC water, followed by PDIO-Sephadex GM25. Fractions were monitored at an OD of 280 nm and using a phenol-sulfuric acid assay for neutral sugars (see later). Fractions containing neutral sugar (6.5-10.5 ml) were pooled, lyophilized, redissolved in 500 IL1 HPLC water (Rathburn Chemicals, Walkerburn, United Kingdom), and filtered through 0.2-pm (pore-size) Anotop IC® filters (Whatman, Maidstone, Kent, United Kingdom).
Mild acid hydrolysis of mucin
Lyophilized colonic mucin (100 pg protein) was subjected to mild acid hydrolysis (0.05 M sulfuric acid, 80'C, for 2 h) to release sialic acid and fucose (15, 29) , followed by resolution of products using PD1O-Sephadex GM25. The hydrolyzed mucin was then subjected to O-glycanase treatment.
Preparation of degalactosylated glycoproteins
Lyophilized samples of colonic mucin (100 pig protein), asialofetuin (0-200 pg), and antifreeze glycopeptides AFGP-I and AFGP-XV (0-100 pg) were incubated with 10 mU bovine testis /3-galactosidase in 100 mM citrate/phosphate buffer, pH 4, for 6 h at 37°C (final volume, 20 pl). Treated glycoproteins, resolved using PD10-Sephadex GM25, were subjected to O-glycanase treatment.
Phenol-sulfuric acid assay for neutral sugars A scaled down version of the method of Dubois et al. (30) was used. 10-pl samples were placed into ELISA microtiter plates (Dynatech Laboratories Inc., Chantilly, VA), agitated with 100 pl 4% wt/vol phenol in distilled water, and left to stand for 5 min. 150 pl of concentrated sulfuric acid was added rapidly (with care) from a fast-delivery multichannel pipette and mixed immediately (five aspirations) to generate a high temperature. Plates were allowed to cool for 20 min and were read at 490 nm. A water blank and standards of 0.5-20 pg galactose (in triplicate) were included in each assay. The between assay coefficient of variation for standards was 7.7% (n = 8).
HPAEC
Sample analysis was performed using a HPLC system coupled with PAD (Dionex UK, Camberley, Surrey, United Kingdom).
Oligosaccharide analysis. Gal/31-3GalNAc was separated using conditions described previously for neutral oligosaccharide alditols (31) . 100-,4l aliquots of O-glycanase reaction products, containing 320 ng of melibiose as internal standard, were injected onto the dual CarboPac PA-100 anion-exchange columns, calibrated with standard Gal, 1- .77 x -0.69 (r = 0.99) using peak height and internal standard ratio quantification analysis. The within assay coefficient of variation was 9.3%, the between assay coefficient of variation was 10.1% (n = 8), and the lower limit of detection for Gal,61 -3GalNAc (I pA output) was 0.02 pg.
In addition, O-glycanase-liberated products were reduced to oligosaccharide alditols using alkaline-borohydride as described previously (31) and reanalyzed using HPAEC-PAD. Samples were compared with reduced standard Galp3l -3GalNAc and with the alditol RI-ol (GalIl3GalNAc-ol) derived from human meconium glycoprotein (15 
Statistical analysis
Sample groups were analyzed using Kruskall-Wallis nonparametric AN-OVA (Arcus Pro-Stat'; Medical Computing, Aughton, Lancashire, United Kingdom). Differences were considered significant when P < 0.05.
Results
Release of Gal/31-3GalNAc (TF antigen) from mucin using 0-glycanase. The treatment of colonic adenocarcinoma mucin with O-glycanase released a saccharide structure with a compatible retention time (using dual column HPAEC) to that of both standard Gal/3l-3GaINAc and Gall-3GaINAc released by O-glycanase from the control TF antigen-expressing substrate AFGP-I (Fig. 1) . Subsequent monosaccharide composition analysis of the O-glycanase released saccharide from adenocarcinoma mucin and AFGP-I, after treatment with bovine testis 46-galactosidase, produced two monosaccharide peaks consistent with galactose and N-acetyl-galactosamine (Fig. 2) of the neutral sugar content, was markedly increased in adenocarcinoma (12.3±2.1 ng Galf61-3GalNAc/tg neutral carbohydrate, 95% CI 7.8-16.9; n = 11, P < 0.0001 ANOVA) and colitic mucin (4.2±0.7 ng/,ug neutral carbohydrate, 95% CI 2.3-6.2; n = 5, P = 0.0018) compared with the histologically normal mucin samples (1.2±0.3 ng/tig neutral carbohydrate, 95% CI 0.48-1.9; n = 9) (Fig. 3) .
After (27) . This study also confirms the increased expression of Gal,61-3GalNAc in premalignant and malignant colonic mucosal disease and its relative lack of expression in histologically normal mucosa, which had previously been demonstrated indirectly by PNA histochemistry (1-9) and the D-galactose oxidase/Schiff's reactivity test (23) . In addition, we have shown an overall reduction in neutral O-glycans of 45% in human adenocarcinoma mucin when compared with histologically normal mucin, a fact consistent with data from a previous study of malignant colonic mucin (32) . There was also a reduction in neutral carbohydrate content seen in ulcerative colitic mucin (32%). Decreased mucin oligosaccharide side-chain length has been observed in active colitis and Crohn's disease (33) and oligosaccharide changes have also been demonstrated by alteration in the binding of anticarbohydrate antibodies and lectins (9, 34, 35) . It is interesting that so far no change in mucin structure has been found in inflammatory bowel disease that has not also been found in colon cancer and in hyperplastic or adenomatous colonic polyps. Although these changes in carbohydrate expression seem likely to be secondary to the disease process, they are likely to have very important functional consequences for mucosal protection (36) , perhaps making the mucus more susceptible to degradation by bacterial mucus-degrading glycosidases which are secreted into the colonic lumen (37) , and provide a good explanation for the marked thinning of the surface mucus layer seen in ulcerative colitis (38) .
The increased availability of Gal,61-3GalNAc for PNA binding in malignancy could be explained either by reduced sialylation (16, 17) or reduced fucosylation (39) of Gal,/1 -3GalNAc, or by a loss of the more common core 3 structure GlcNAc/31 -3GalNAc (22) , allowing preferential synthesis of core 1, Gal,31-3GalNAc. Evidence from the present study, that mild acid hydrolysis reveals TF antigen in normal mucin, would suggest reduced sialylation or fucosylatiom as the mechanism, but a recent study has reported reduced 631-3GlcNAc -GalNAc transferase but unchanged 61-3Gal --GalNAc transferase in colorectal carcinoma cells (40) . It is quite likely that different mechanisms account for TF expression in different situations. Little is currently known about the mechanisms which regulate the relevant glycosyltransferases but ras oncogene transformation has been shown to result in decreased a2 -3 --Gal,8 1- 3GalNAc sialyltransferase activity (41) .
Mucins are the predominant glycoproteins secreted by colonic epithelium and unlike most membrane-bound glycoconjugates they can be isolated in sufficient quantity to permit biochemical analysis of their carbohydrate. However, histochemical studies suggest that changes in O-glycosylation of epithelial mucin are often paralleled by similar changes in the O-glycosylation of epithelial cell-surface glycoconjugates (3). We have recently proposed that increased TF antigen expression on hyperplastic and malignant epithelial cell-surface glycoconjugates may have functional significance by allowing interaction with Gal/31-3GalNAc-binding lectins of dietary and microbial origin. These lectins can have marked effects on proliferation and mucosal metabolism. PNA, which resists digestion in the mammalian intestine, stimulates proliferation and mucus synthesis in vitro ( 10-12). Likewise, anti-TF monoclonal antibodies have been shown to produce similar marked effects on colorectal cancer cell line proliferation (42) . Moreover, in a recent study we have shown that ingestion of peanuts for 1 wk resulted in an increased rectal mitotic index of 40% in the one third of subjects (mainly irritable bowel syndrome) who had identifiable expression of PNA receptor by the histologically normal colonic mucosa (43) . Other Gal-GalNAc-binding lectins, such as edible mushroom (Agaricus bisporus) and jack fruit (jacalin) lectins, cause noncytotoxic inhibition of proliferation of colorectal cell lines (44, 45). Therefore, it seems likely that the interaction of luminal dietary and microbial lectins with TF-expressing epithelial cells could be quantitatively as important as interaction with growth factors in determining the increased proliferation that occurs in hyperplasia and as a prelude to malignant change. Further studies are required to determine those glycosyltransferase changes which account for the increased expression of TF antigen.
